• TeamViewer Al summarized more than 270,000 remote support sessions, enabling proactive IT management and increasing productivity for customers
• Number of session summaries increased 4x from May – July to Aug – Oct
• Approximately 10,000 customers signed up to use TeamViewer AI; 60% growth of active AI users from Sept to Oct; 400% growth since July
• Customers report substantial efficiency gains like 25% faster issue resolution 
• Building a unique agentic proposition based on differentiated proprietary data

GOPPINGEN, Germany, Nov. 5, 2025 /PRNewswire/ — TeamViewer, a global leader in digital workplace solutions, reports significant adoption of its artificial intelligence (AI) offering, only three months after a first promotion of the product. To date, TeamViewer AI has automatically summarized more than 270,000 IT support sessions. From August to October 2025, session summaries grew 4x versus the previous three months. TeamViewer AI customers report substantial efficiency gains, including 5-10 minutes of documentation work saved per IT ticket and up to 25% faster issue resolution.

These sessions were generated by c. 10,000 customers who opted in to use TeamViewer’s Al features. From September to October, the number of customers actively using these features grew by 60%. From July to October, active users grew by 400%.

As a pioneer in secure remote connectivity and leader in Digital Employee Experience (DEX) management, TeamViewer is well-positioned to use its differentiated set of proprietary data to build further AI momentum. The company has more than 645,000 paying customers, more than 1 billion remote connections to a multitude of devices each year and access to telemetry data of millions of devices, where a TeamViewer DEX client is monitoring device health and performance and automatically remediating IT issues in real-time.

Mei Dent, TeamViewer’s CPTO, said: “Over the last 20 years, TeamViewer has become synonymous with secure remote connectivity and support. By integrating 1E’s real-time auto-remediation capabilities and evolving our core business to become proactive and autonomous we are building the go-to company for IT support and endpoint management in the era of agentic AI. The rapid adoption of our AI solutions so far demonstrates the real ROI this is already delivering for our customers.”

TeamViewer will be exhibiting at this year’s Microsoft Ignite conference in San Francisco (18th-25th Nov 2025) and showcasing its complete Al offering including the next innovation around autonomous Al agents for IT support (Booths #5445 & #1527).

About TeamViewer

TeamViewer provides a Digital Workplace platform that connects people with technology – enabling, improving and automating digital processes to make work work better.

In 2005, TeamViewer started with software to connect to computers from anywhere to eliminate travel and enhance productivity. It rapidly became the de facto standard for remote access and support and the preferred solution for hundreds of millions of users across the world to help others with IT issues. Today, more than 645,000 customers across industries rely on TeamViewer to optimize their digital workplaces – from small to medium-sized businesses to the world’s largest enterprises – empowering both desk-based employees and frontline workers. Organizations use TeamViewer’s solutions to prevent and resolve disruptions with digital endpoints of any kind, securely manage complex IT and industrial device landscapes, and enhance processes with augmented reality powered workflows and assistance – leveraging Al and integrating seamlessly with leading tech partners. Against the backdrop of global digital transformation and challenges like shortage of skilled labor, hybrid working, accelerated data analysis, and the rise of new technologies, TeamViewer’s solutions offer a clear value add by increasing productivity, reducing machine downtime, speeding up talent onboarding, and improving customer and employee satisfaction.

The company is headquartered in Göppingen, Germany, and employs more than 1,900 people globally. In 2024, TeamViewer achieved a revenue of around EUR 671 million. TeamViewer SE (TMV) is listed at Frankfurt Stock Exchange and belongs to the MDAX. Further information can be found at www.teamviewer.com. 

Press contact:
Martina Dier
press@teamviewer.com 

• BioDlink helps Lepu Biopharma win China’s marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma
• This Becotatug Vedotin injection approval is BioDlink’s first commercial ADC manufacturing initiative worldwide, validating its complex biologics commercialization capabilities

SUZHOU, China, Nov. 5, 2025 /PRNewswire/ — BioDlink (1875.HK) congratulates its partner Lepu Biopharma (2157.HK) on receiving conditional marketing approval from China’s National Medical Products Administration (NMPA) for MEIYOUHENG (Becotatug Vedotin injection). This Class 1 innovative antibody-drug conjugate (ADC) targets the epidermal growth factor receptor (EGFR) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Significantly, this is the world’s first approved non-photoimmunological EGFR-targeted ADC and a first-in-class innovation. This project is BioDlink’s first commercial ADC manufacturing initiative globally, validating its robust capabilities in the commercialization of complex biologics.

This approval builds on BioDlink’s earlier success with Lepu Biopharma’s ADC program that achieved 100% first-pass success across technology transfer, Process Performance Qualification (PPQ), and Pre-Approval Inspection (PAI).

The program, designated as a Breakthrough Therapy Project, required rapid tech transfer and full production line delivery from monoclonal-antibody Drug Substance through ADC Drug Product.

BioDlink’s performance in this project secured BLA approval on October 30, 2025, demonstrating its capacity to meet aggressive regulatory timelines and ensure commercial readiness for global markets.

ADC manufacturing is technologically demanding, requiring exceptional process capabilities and robust quality systems. BioDlink participated in the entire development and production cycle, from technology transfer, process development, and analytical method establishment to clinical sample and GMP-compliant commercial batch manufacturing. This reflects the company’s end-to-end capabilities in supporting complex biologics from R&D to market launch.

Through close coordination with Lepu Biopharma and multiple regulatory authorities, BioDlink established an integrated quality management system. This system ensures seamless coordination across the entire production chain—accelerate the timeline for pivotal clinical batch production and subsequent PPQto meet aggressive regulatory submission goals and aligns with global GMP standards, including those of China, the U.S., and the EU. BioDlink’s manufacturing facilities have obtained GMP certifications from several countries and Foreign Manufacturer Approval from Japan’s PMDA. This collaboration sets a practical model for efficient multi-party industry collaboration and resource integration in the biopharma sector.

BioDlink’s manufacturing facilities have obtained GMP certifications from China, Brazil, Argentina, Indonesia, Egypt, Colombia, Pakistan and Thailand, as well as Foreign Manufacturer Approval from Japan’s PMDA. And also passed EU-QP 5 times in these years. This achievement marks a major step forward for ADC commercialization and demonstrates a practical model for multi-party industry collaboration and efficient resource integration.

Dr. Ziye Sui, Executive Director and CEO of Lepu BioPharma, commented: “We sincerely thank the BioDlink team for their outstanding CDMO services and strong collaboration. This approval also establishes a practical pathway for multi-party collaboration, offering new hope for R/M NPC patients who have failed anti-PD-(L)1 and platinum-based therapies.”

Dr. Jian Zhang, Chief Operating Officer, BioDlink, noted: “The approval of this pilot batch highlights the increasing technical and quality coordination demands placed on both the Marketing Authorization Holder (MAH) and the CDMO. Moving forward, we will continue working closely with our partners to accelerate the launch of innovative medicines to benefit patients worldwide.”

About Becotatug Vedotin

MEIYOUHENG (Becotatug Vedotin injection) is an ADC comprised of an EGFR-targeted monoclonal antibody conjugated with the potent microtubulin inhibiting payload monomethyl auristatin E via a valine-citrulline linker. It is the world’s first approved EGFR-targeted ADC and a first-in-class innovation, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

It binds specifically with high affinity to EGFR on the surface of tumor cells, releases the potent payload upon internalization and lysosomal protease cleavage of the linker and results in tumor cell death. EGFR is highly expressed in colorectal cancer, lung cancer, head and neck cancer and other malignant solid tumors, and is expressed in 89% advanced NPC. Therefore, EGFR is an important target for cancer treatment.

About Lepu Biopharma

Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) is an innovation-driven company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. The company is dedicated to developing innovative ADCs through its advanced ADC technology platform. Lepu Biopharma highly values the continuing build-out of its own commercialization capabilities and is determined to pursue the goal towards strong transformation from core technology to drugs and industrialization. At present, the product pipeline of Lepu Biopharma covers three major areas, namely immunotherapies, ADC targeted therapies and oncolytic virus drugs, including two commercialization- stage drug candidates, eigth clinical-stage drug candidates (six of which are ADC drug candidates) and three clinical-stage combination therapies of the key candidates in its pipeline. The company houses the leading ADC drug candidate pipeline in China.

About BioDlink Biopharm Co., Ltd.

BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing.

With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, and Colombia.

Guided by the philosophy of “Quality First, Innovation Driven, Success Together,” BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://www.biodlink.com/

• Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics
• Strengthening global CDMO strategy through strategic synergy with SK bioscience
• Sustainable growth expected, backed by European commercial manufacturing infrastructure and regulatory expertise

FRANKFURT, Germany, VIENNA and SEONGNAM, South Korea, Nov. 5, 2025 /PRNewswire/ — IDT Biologika GmbH (IDT), the European subsidiary of SK bioscience, has embarked on a full-scale drive to expand its global contract development and manufacturing (CDMO) business in vaccines and biopharmaceuticals.

In October and early November, IDT participated in three of the industry’s leading global events — the World Vaccine Congress Europe 2025 (WVC) in Amsterdam, the CPHI Frankfurt 2025 (Convention on Pharmaceutical Ingredients) in Germany, and the ongoing BIO-Europe 2025 in Vienna — where the company presented its comprehensive end-to-end manufacturing solutions and global partnership strategies, spanning from early development to full commercial production.

At WVC 2025, one of the world’s largest vaccine conferences covering from R&D through commercialization, IDT held partnering meetings with global pharmaceutical companies and research institutes, highlighting its integrated capabilities in cell-culture and microbial-based processes, process development, quality validation, and fill-finish operations. Furthermore, the company shared how IDT developed a tailored in-house assay for high-sensitivity quantification and reliable sizing of host cell DNA.

Aligning with this year’s congress theme, “Connecting Innovation from Research to Commercial Manufacture,” the company emphasized its scalable CDMO platform supporting not only vaccines but also next-generation modalities such as gene and immune therapeutics and monoclonal antibodies.

During CPHI 2025, under the theme “Trusted Manufacturing Expertise with a Strong Partnership Commitment,” IDT underscored its flexible production infrastructure, reliable supply chains, and extensive experience with European and global regulatory frameworks, reinforcing its position as a trusted CDMO partner for clients worldwide.

At BIO-Europe 2025, Europe’s largest biopharmaceutical partnering conference, IDT focused on its drug-substance and drug-product manufacturing solutions for sterile injectables. The company showcased its aseptic production technologies, advanced process know-how, and integrated CDMO services supporting development through commercialization, while engaging in partnering discussions with global clients.

Through these three events, IDT strengthened its role as a strategic manufacturing partner providing tailored, end-to-end solutions, moving beyond traditional contract production. Leveraging its collaboration with SK bioscience, the company is accelerating efforts to expand global partnerships and project acquisitions.

“WVC, CPHI and BIO-Europe are key global stages for the vaccine and biopharmaceutical industry, where IDT demonstrated its manufacturing excellence and partnership capabilities,” said Dr. Sally Choe, Co-CEO of IDT Biologika.

“Guided by our vision to be ‘The reliable partner in creating a healthier world,’ we will continue to advance customer-centric strategies and long-term partnerships to further strengthen our presence in the global CDMO market.”

Since SK bioscience acquired a 60% stake in IDT Biologika last year, the two companies have integrated their development, manufacturing, and supply-chain operations across vaccines and advanced biopharmaceuticals, enhancing the competitiveness of their global CDMO network.

The combination of SK bioscience’s recombinant protein and cell-culture technologies with IDT’s European commercial manufacturing infrastructure and regulatory expertise has significantly improved operational efficiency and profitability. Industry observers expect IDT to achieve a full-year operating profit in 2025, marking a turnaround driven by this synergy.

Looking ahead, IDT Biologika plans to continue expanding its global CDMO footprint together with SK bioscience, reinforcing its position as a worldwide manufacturing hub for vaccines and advanced therapeutics and building a sustainable network spanning Europe, the Americas and Asia.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

– SK bioscience Website
– SK bioscience Linkedin

Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)  
Mooncheol Kim (MC_kim@sk.com)  

CHICAGO, Nov. 5, 2025 /PRNewswire/ — Thoughtworks, a global technology consultancy that integrates design, engineering and AI to drive digital innovation, today released volume 33 of the Technology Radar, a biannual report informed by the organizations’ experiences with clients. This edition spotlights the rapid evolution of AI assistance in today’s enterprise and showcases the techniques and technologies driving change this year. 

Thoughtworks Technology Radar Volume 33

More specifically, this volume points to increasing consolidation in the form of ‘context engineering’, new protocols like MCP and the growth of agentic systems — that’s in contrast to volume 32, published in April, which instead highlighted emergent practices, such as retrieval augmented generation and prompt engineering. This shift from one volume to the next is a signal that AI is rapidly maturing in the software engineering space.

However, while the report notes successful applications of generative AI, such as helping teams understand legacy codebases, it also emphasizes both the infrastructural demands of these systems and, worryingly, the growth of AI-related antipatterns. The takeaway for technologists and business leaders alike should be clear: AI success depends on rigor and attention to detail and nothing is inevitable.

“AI has dominated the last few editions of the Technology Radar but volume 33 marks a step change in how the industry is thinking about it,” said Rachel Laycock, Chief Technology Officer of Thoughtworks. “At the start of the year, the industry couldn’t stop talking about vibe coding — where developers provide prompts that feel right to an AI and expect software to come out the other end. That’s practically disappeared; we now see a concerted and serious effort to think through problems of context, infrastructure and security. The whole of this year has been a live experiment in AI — we’re now beginning to see benefits.”

The themes in Technology Radar Volume 33 include:

The rise of agents elevated by Model Context Protocol (MCP): Every major technology vendor is building agent-awareness into their platforms, largely thanks to the Model Context Protocol (MCP). MCP is a hugely popular integration protocol that allows agents to work efficiently and semi-autonomously; it’s transforming how teams approach software development, creating the foundations for agent-assisted workflows.

Infrastructure orchestration arrives for AI: The explosion of AI workloads is forcing platform teams to orchestrate large fleets of GPUs for both training and inference. As a consequence, GPU-aware orchestration is now a competitive necessity.

AI coding workflows: AI is strategically embedding itself across the entire software development value chain. Success is being driven by teams discovering new ways to manage context with coding agents and share knowledge and practices with others.

AI antipatterns: As AI tools become more prevalent, organizations are encountering new challenges such as AI-accelerated shadow IT and complacency with AI-generated code. This calls for sustained human judgment, oversight and healthy skepticism if organizations are to avoid negative downstream consequences.

Visit www.thoughtworks.com/radar to explore the interactive version of the Radar or download the PDF version.

Supporting resources:

• Read more about the macro trends in the tech industry in this edition.
• Keep up with Thoughtworks news by visiting the company’s website.
• Follow Thoughtworks on X, LinkedIn and YouTube.

About Thoughtworks
Thoughtworks is a global technology consultancy that integrates design, engineering and AI to drive digital innovation. We are over 10,000 Thoughtworkers strong across 47 offices in 18 countries. For 30+ years, we’ve delivered extraordinary impact together with our clients by helping them solve complex business problems with technology as the differentiator.

Media contact:
Michelle Surendran, head of public relations for Thoughtworks APAC and India
Email: michels@thoughtworks.com

To commemorate two decades since its groundbreaking 3-in-1 coffee press debuted, the iconic coffee press is expanding its lineup with new Premium colorways and a compact, high-performance Manual Coffee Grinder

PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ — Two decades of great-tasting coffee calls for a celebration and AeroPress, Inc. is marking the milestone by unveiling all-new products designed to enhance the brewing experience, including the brand’s first Manual Coffee Grinder and the popular AeroPress Premium in new Black and White color variants.

AeroPress Expands its Lineup with First-Ever Manual Coffee Grinder

The pro-level, ultra-compact Manual Grinder promises the same precision, versatility, portability and ease-of-use that the brand is known for, delivering effortlessly smooth, consistent results across every brew method—from espresso and AeroPress to pour-over, moka pot and French press. No matter how you brew, it’s designed to elevate your coffee ritual. The introduction marks the brand’s first-ever expansion beyond manual brewers and into a broader portfolio of high-performance coffee gear.

Its ground-breaking design delivers:

• Brew Precision: Designed with 60+ grind settings for full control from espresso-fine to cold brew-coarse.
• Premium Performance and Materials: Engineered with Italian-made 38mm titanium-coated burrs for maximum durability and an ultra-consistent grind.
• Ultra-Portability: Inch-for-inch the most compact high-performance grinder on the market. The grinder fits inside an AeroPress, including the magnetic handle, making it the ultimate travel companion for both coffee lovers and industry professionals.
• Ease of Use: Features a patent-pending, extra-long ergonomic handle with dual bearings for effortless grinding. A slim build makes it easy to grip and perfect for large and small hands alike.
• Lifetime Burr Warranty: Engineered for long-term performance and precision grinding, AeroPress backs the burrs with a lifetime warranty—plus a two-year warranty on all other components upon registration.

The brand’s award-winning Premium is the most sought-after release ever introduced by AeroPress—selling out in record time. The new Black and White editions build off that success – made from the same hand-crafted double wall borosilicate glass and metal with subtle, laser-etched branding, combining elevated aesthetics with the brand’s patented 3-in-1 brew technology. Delivering the smoothness of a pour-over, the full body of a French press and the richness of espresso in under two minutes, the Premium edition, now available in three colors, offers the perfect gift for coffee lovers who value their kitchen aesthetic and appreciate great design and even better-tasting coffee.

“Throughout our 20-year history, AeroPress has been committed to delivering products that help consumers brew better,” said Gerard Meyer, CEO of AeroPress. “We’ve applied the same design ethos of flavor, precision, versatility and portability that has made our compact brewers iconic to create a manual grinder that delivers professional performance in a travel-friendly form, as well as answered fans’ calls for a coffee maker that combines both functionality and stylish design with our new Premium colors.”  

David Cole, CMO of AeroPress, added: “Launching the Manual Grinder and latest Premium colorways alongside our 20th Anniversary demonstrates AeroPress’ evolution as a brand and our commitment to our fans. We worked closely with a group of baristas, competitors, and coffee professionals to validate every choice in making the Manual Grinder—from Italian-made titanium-coated burrs to 60+ precise grind settings—to ensure our promise of a high-performance and reliably versatile coffee experience. Their insights helped fine-tune each element, so it performs at the highest standards anywhere you brew.”

Both the Manual Grinder ($199.95 USD) and Premium Black and White editions ($199.95 USD) are available now from distributors around the world and on Amazon Europe in select markets, with greater global distribution coming soon.

For more information about AeroPress, new products and brew methods, visit aeropress.com or follow along on Instagram, TikTok, YouTube and Pinterest. 

ABOUT AEROPRESS 
AeroPress was invented by engineer Alan Adler, who set out to create a better way to brew a single cup of coffee — smoother, more flavorful and faster. His breakthrough, air pressure, sped up extraction and reduced bitterness, unlocking the full flavor of the coffee bean in every cup.

Part French Press, part Pour-Over and part Espresso, AeroPress uses patented 3-in-1 brew technology that combines immersion, air pressure and micro-filtration. The result: a clean, full-bodied cup with less bitterness and no grit, brewed in under 60 seconds.

Unlike traditional brewing methods, AeroPress offers complete control over every variable — enabling recipes from cold brew and iced coffee to rich espresso-style drinks like cappuccinos and lattes. With its travel-friendly design and fast brewing process, AeroPress has become a favorite of baristas, world champions and everyday coffee lovers. More than 75,000 five-star reviews and the fan-fueled World AeroPress Championship — the largest filtered coffee competition in the world, spanning 70+ countries — underscore its global impact.

To learn more, visit aeropress.com or follow us on Instagram, TikTok, YouTube and Pinterest. 

Aeropress Unveils Popular Aeropress Premium in New Black and White Color Variants

SHENZHEN, China, Nov. 5, 2025 /PRNewswire/ — RoboUP has officially announced its latest innovation in smart lawn care — the Raccoon 2 SE, now in its last 7 days pre-launch phase on Kickstarter. Described as a life-changing innovation, the Raccoon 2 SE aims to make modern lawn care accessible to everyone. For the price of a coffee machine, three weeks of groceries, or a pair of AirPods, homeowners can now own a fully automatic lawn mower robot. 

What Makes the Raccoon 2 SE Robot Mower Different?

In a market dominated by oversized, high-priced models built for larger lawns, RoboUP’s Raccoon 2 SE stands out as a refreshing alternative. Raccoon 2 SE is affordable because it’s built around small-garden needs. Most of these gardens have clear boundaries and simple terrain, allowing a vision-based system to deliver great mowing results without unnecessary high-cost tech. This keeps prices low while still offering effortless, hands-free lawn care.

A Perfect Lawn Mower for Small Lawns — Without the Premium Price Tag

By prioritizing simplicity, RoboUP aims to make life easier for everyday homeowners. Industry experts and beta testers have already tested the Raccoon 2 SE, demonstrating its real-world performance and reliability.

Industry Expert Reviews

“For simple, clearly defined lawns, the RoboUP Raccoon 2 SE proved to be a recommendable and attractively priced helper.”
— Handyhase.de

“Its greatest strength lies in its simple start-up. Just unpack, power on, and start mowing. Combined with the optional but highly recommended App, reliable obstacle detection, and quiet operation, it makes lawn care virtually maintenance-free.”
— Basictutorials.com

“The Raccoon 2 SE offers an excellent overall package, especially for small and medium-sized areas.”
— Gartenzeile, YouTuber (Germany)

Beta Tester Comments

“Perfect parallel mowing, drives smoothly through fallen leaves.”
— Christian E., Germany

“It’s been the ideal solution for my backyard.”
— Basim D., USA

“Obstacle avoidance works great so far!”
— Eric V., France

Discover more on RoboUP Youtube Channel and join the campaign on Kickstarter.

What’s Trending: Simplicity Is the New Smart

RoboUP’s Raccoon 2 SE embodies this shift, built for those who value ease over excess. It offers an optional App-free experience with no boundary wires, no RTK installation, and no setup required. Taking convenience to the next level, the Raccoon 2 SE delivers instant mowing, auto-mapping, and self-charging, creating a truly hands-free experience for small lawns with clear physical boundaries. The slogan of ‘Just Press Play’ embodies this, as you can now press one button and walk away, without having to deal with anything else, a true plug and play experience.

The Raccoon 2 SE will launch on Nov. 11^th 2025 and there is only 7 days left for early supporters! Reserve your Super Early Bird spot now with a fully refundable $20 deposit to lock in your price starting from just $299. Because everyone deserves smart lawn care, without the high price or tech headaches.

Click here to reserve your $299 Super Early Bird deal with a refundable deposit of $20, or set a Kickstarter launch reminder here.